Most importantly, it would be relevant to assess whether a long-term treatment with appropriated doses of fluoxetine (20–40 mg/die) can improve cognitive function in DS individuals by the rescue of TGF-β1. This evidence concerns the gene TGFB1 and Dravet syndrome.